S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
Log in
CVE:AQS

Aequus Pharmaceuticals Stock Forecast, Price & News

C$0.22
0.00 (0.00 %)
(As of 03/8/2021 01:03 PM ET)
Add
Compare
Today's Range
C$0.21
Now: C$0.23
C$0.23
50-Day Range
C$0.13
MA: C$0.19
C$0.28
52-Week Range
C$0.07
Now: C$0.23
C$0.29
Volume61,842 shs
Average Volume932,260 shs
Market CapitalizationC$26.68 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistita, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid-based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; Mynosys Cellular Devices for distribution, sales and marketing of Zepto for cataract surgery; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was founded in 2013 and is headquartered in Vancouver, Canada.

Headlines

Aequus Closes $1 Million Financing
February 26, 2021 |  finance.yahoo.com
Aequus Announces Anne Stevens' Leadership Change
November 14, 2020 |  benzinga.com
Aequus Pharmaceuticals Inc. Reg (AEQ.SG)
October 10, 2020 |  au.finance.yahoo.com
Aequus Pharmaceuticals Inc.
September 11, 2020 |  barrons.com
Aequus Completes C$2.5 million Equity Financing
August 6, 2020 |  benzinga.com
Aequus Announces "Best Efforts" Public Offering
July 28, 2020 |  www.benzinga.com
Aequus Pharmaceuticals: The Moment Is Now
July 24, 2020 |  seekingalpha.com
A Message from the CEO of Aequus Pharmaceuticals
March 23, 2020 |  www.globenewswire.com
See More Headlines

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-604-3367906
Employees10
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$2.28 million
Cash FlowC$0.02 per share
Book ValueC$0.01 per share

Profitability

Miscellaneous

Market CapC$26.68 million
Next Earnings Date5/5/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

0.85 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
C$0.22
0.00 (0.00 %)
(As of 03/8/2021 01:03 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AQS News and Ratings via Email

Sign-up to receive the latest news and ratings for AQS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aequus Pharmaceuticals (CVE:AQS) Frequently Asked Questions

What stocks does MarketBeat like better than Aequus Pharmaceuticals?

Wall Street analysts have given Aequus Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aequus Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Aequus Pharmaceuticals' next earnings date?

Aequus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Aequus Pharmaceuticals
.

How has Aequus Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Aequus Pharmaceuticals' stock was trading at C$0.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AQS stock has increased by 104.5% and is now trading at C$0.23.
View which stocks have been most impacted by COVID-19
.

Who are Aequus Pharmaceuticals' key executives?

Aequus Pharmaceuticals' management team includes the following people:
  • Mr. Douglas Glen Janzen, Chairman, CEO & Pres (Age 52, Pay $191.25k)
  • Ms. Ann Fehr CGA, CPA, CFO & Corp. Sec. (Age 52, Pay $123.95k)
  • Mr. Stuart Fowler, Strategic Commercial Advisor & Independent Director
  • Mr. Grant Larsen, Chief Commercial Officer

Who are some of Aequus Pharmaceuticals' key competitors?

What other stocks do shareholders of Aequus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aequus Pharmaceuticals investors own include GrowLife (PHOT), Terra Tech (TRTC), Abbott Laboratories (ABT), Acorn Energy (ACFN), Crown Castle International (CCI), Charlotte's Web (CWBHF), (FIRE.V) (FIRE), LiCo Energy Metals (LIC), Marijuana Company of America (MCOA) and Planet 13 (PLNHF).

What is Aequus Pharmaceuticals' stock symbol?

Aequus Pharmaceuticals trades on the Canadian Venture Exchange (CVE) under the ticker symbol "AQS."

How do I buy shares of Aequus Pharmaceuticals?

Shares of AQS and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Aequus Pharmaceuticals' stock price today?

One share of AQS stock can currently be purchased for approximately C$0.23.

How much money does Aequus Pharmaceuticals make?

Aequus Pharmaceuticals has a market capitalization of C$26.68 million and generates C$2.28 million in revenue each year.

How many employees does Aequus Pharmaceuticals have?

Aequus Pharmaceuticals employs 10 workers across the globe.

What is Aequus Pharmaceuticals' official website?

The official website for Aequus Pharmaceuticals is www.aequuspharma.ca.

Where are Aequus Pharmaceuticals' headquarters?

Aequus Pharmaceuticals is headquartered at 2820-200 Granville St, VANCOUVER, BC V6C 1S4, Canada.

How can I contact Aequus Pharmaceuticals?

Aequus Pharmaceuticals' mailing address is 2820-200 Granville St, VANCOUVER, BC V6C 1S4, Canada. The company can be reached via phone at +1-604-3367906.


This page was last updated on 3/9/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.